US Patent 11608380 Anti-EGFRvIII antibodies and uses thereof
Patent 11608380 was granted and assigned to Regeneron Pharmaceuticals on March, 2023 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11608380 Anti-EGFRvIII antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
